BillionToOne, Inc. Class A Common Stock BLLN
HEALTHCARE · DIAGNOSTICS & RESEARCHi
Market dataready · fetched 2026-11-13T02:53:31.743Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-12T21:00:03.451820322Z
FundamentalsAlpha Vantage · ready · quarter 2026-09-30 · fetched 2026-11-13T02:53:31.407667+00:00
BillionToOne, Inc. Class A Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 128.51 | 106.1% | 17.6% | 98.49 | 103.7% | 13.0% |
| 25Δ | 123.87 | 95.7% | 13.7% | 101.08 | 103.7% | 11.3% |
| 30Δ | 119.61 | 86.4% | 10.2% | 103.53 | 101.9% | 9.7% |
| 35Δ | 117.29 | 82.4% | 8.6% | 105.84 | 98.2% | 8.2% |
| 40Δ | 114.97 | 78.4% | 6.9% | 107.93 | 91.5% | 6.7% |
| 45Δ | 113.32 | 76.6% | 5.9% | 110.01 | 84.9% | 5.3% |
| 50Δ | 111.68 | 74.7% | 5.0% | 111.85 | 85.8% | 4.6% |
| 55Δ | 110.03 | 72.9% | 4.0% | 113.68 | 86.7% | 4.0% |
| 60Δ | 108.43 | 73.6% | 3.4% | 115.68 | 88.3% | 3.4% |
| 65Δ | 106.83 | 74.4% | 2.9% | 118.11 | 92.0% | 2.9% |
| 70Δ | 105.22 | 75.3% | 2.3% | 120.40 | 93.6% | 2.4% |
| 75Δ | 103.43 | 74.6% | 1.9% | 122.19 | 88.5% | 1.8% |
| 80Δ | 101.61 | 73.7% | 1.4% | 123.98 | 83.3% | 1.3% |
20Δ
- Pseudo strike
- 128.51
- IV
- 106.1%
- B/E move
- 17.6%
- Pseudo strike
- 98.49
- IV
- 103.7%
- B/E move
- 13.0%
25Δ
- Pseudo strike
- 123.87
- IV
- 95.7%
- B/E move
- 13.7%
- Pseudo strike
- 101.08
- IV
- 103.7%
- B/E move
- 11.3%
30Δ
- Pseudo strike
- 119.61
- IV
- 86.4%
- B/E move
- 10.2%
- Pseudo strike
- 103.53
- IV
- 101.9%
- B/E move
- 9.7%
35Δ
- Pseudo strike
- 117.29
- IV
- 82.4%
- B/E move
- 8.6%
- Pseudo strike
- 105.84
- IV
- 98.2%
- B/E move
- 8.2%
40Δ
- Pseudo strike
- 114.97
- IV
- 78.4%
- B/E move
- 6.9%
- Pseudo strike
- 107.93
- IV
- 91.5%
- B/E move
- 6.7%
45Δ
- Pseudo strike
- 113.32
- IV
- 76.6%
- B/E move
- 5.9%
- Pseudo strike
- 110.01
- IV
- 84.9%
- B/E move
- 5.3%
50Δ
- Pseudo strike
- 111.68
- IV
- 74.7%
- B/E move
- 5.0%
- Pseudo strike
- 111.85
- IV
- 85.8%
- B/E move
- 4.6%
55Δ
- Pseudo strike
- 110.03
- IV
- 72.9%
- B/E move
- 4.0%
- Pseudo strike
- 113.68
- IV
- 86.7%
- B/E move
- 4.0%
60Δ
- Pseudo strike
- 108.43
- IV
- 73.6%
- B/E move
- 3.4%
- Pseudo strike
- 115.68
- IV
- 88.3%
- B/E move
- 3.4%
65Δ
- Pseudo strike
- 106.83
- IV
- 74.4%
- B/E move
- 2.9%
- Pseudo strike
- 118.11
- IV
- 92.0%
- B/E move
- 2.9%
70Δ
- Pseudo strike
- 105.22
- IV
- 75.3%
- B/E move
- 2.3%
- Pseudo strike
- 120.40
- IV
- 93.6%
- B/E move
- 2.4%
75Δ
- Pseudo strike
- 103.43
- IV
- 74.6%
- B/E move
- 1.9%
- Pseudo strike
- 122.19
- IV
- 88.5%
- B/E move
- 1.8%
80Δ
- Pseudo strike
- 101.61
- IV
- 73.7%
- B/E move
- 1.4%
- Pseudo strike
- 123.98
- IV
- 83.3%
- B/E move
- 1.3%
Options history
Table
| Date | IV (%) |
|---|---|
| 62.01% | |
| 62.03% | |
| 67.61% | |
| 65.08% | |
| 63.95% | |
| 66.24% | |
| 64.70% | |
| 65.85% | |
| 65.47% | |
| 62.53% | |
| 65.36% | |
| 65.60% | |
| 65.20% | |
| 63.97% | |
| 64.74% | |
| 67.71% | |
| 65.77% | |
| 65.11% | |
| 64.91% | |
| 68.98% | |
| 69.06% | |
| 70.60% | |
| 68.30% | |
| 64.68% | |
| 64.60% | |
| 63.96% | |
| 63.73% | |
| 64.76% | |
| 65.18% | |
| 66.15% | |
| 66.30% | |
| 65.62% | |
| 65.73% | |
| 65.29% | |
| 65.77% | |
| 65.13% | |
| 67.06% | |
| 65.02% | |
| 67.26% | |
| 70.32% | |
| 75.49% | |
| 71.60% | |
| 68.82% | |
| 69.40% | |
| 67.89% | |
| 68.19% | |
| 69.30% | |
| 71.55% | |
| 72.78% | |
| 72.31% | |
| 71.93% | |
| 71.72% | |
| 73.43% |
Diagnostics & Research
CDNA
CareDx, Inc. discovers, develops and markets diagnostic solutions for transplant patients and caregivers globally. The company is headquartered in South San Francisco, California.
More →CRL
Charles River Laboratories International, Inc., is an American pharmaceutical company specializing in a variety of preclinical and clinical laboratory, gene therapy and cell…
More →CSTL
Castle Biosciences Inc. is a pioneering diagnostics firm that enhances patient care through advanced gene-expression profiling tests, particularly within the skin cancer sector,…
More →DGX
Quest Diagnostics is an American clinical laboratory. A Fortune 500 company, Quest operates in the United States, Puerto Rico, Mexico, and Brazil. Quest also maintains…
More →DHR
Danaher Corporation is an American globally diversified conglomerate with its headquarters in Washington, D.C.. The company designs, manufactures, and markets professional,…
More →FLGT
Description unavailable
More →